Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

-3.75 0.47 5.53 8.94 p = 0.002 WASO -1.86 -12.69 -14.31 -33.22 p = 0.001 TST -9.22 4.17 0.56 27.61 p < 0.001 Total Time Awake 9 -4.08 -1.42 -28.31 p < 0.001 Sleep Efficiency -1.94 0.82 0.14 5.80 p < 0.001

The effects of ITI-007 on SWS are likely due to the ability of ITI-007 to potently antagonize 5HT2A receptors at low doses. The expanded pharmacological effects that emerge at higher doses contributed to the robust decreases in WASO at the 10 mg dose of ITI-007. The magnitude of this effect on WASO is larger than that seen with selective 5HT2A receptor antagonists and may be attributed to additional beneficial pharmacology that emerges at the higher doses tested. The highest dose tested (10 mg) is thought to fully occupy 5HT2A receptors while adding incremental amounts of dopamine receptor and serotonin reuptake transporter (SERT) occupancy. Together, these data suggest that ITI-007 induces a novel pattern of sleep improvement.

Doses of ITI-007 were safe and well-tolerated in patients with insomnia. The majority of the subjects experienced no adverse events (58%) or adverse events that were considered unrelated or unlikely related to study treatment (26%). Only 3 of the 19 subjects (16%) experienced an adverse event considered possibly related to study treatment; these were mild to moderate, were not dose-related and all resolved. No serious adverse events were reported. Importantly, ITI-007 did not impair next day cognition as measured by a battery of cognitive testing in the morning upon waking. ITI-007 caused no significant impairment of attention, vigilance, information processing or declarative memory as measured by the Leeds Psychomotor Battery, Digit Symbol Substitution Test or Word Pair Associates Test. Pharmacokinetic analyses
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
(Date:5/28/2015)... MADISON, N.J. , May 28, 2015  Quest ... provider of diagnostic information services, announced that it is ... Conference in New York.  Steve Rusckowski , the ... goals and five point strategy.  The presentation is scheduled ... Time. The presentation will be webcast live ...
(Date:5/28/2015)... May 27, 2015 Research and ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3
... Inc. (Nasdaq: ALXN ), today announced that the ... on Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time ... for the second quarter ended June 30, 2008. Alexion,anticipates ... Tuesday,July 29, 2008., To participate in this conference ...
... China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), a ... company with operations in China and the United,States, today ... 20 "China Most,Innovative Enterprises" and its CEO Dr. Ge ... Leaders of Chinese Enterprises" at the 8th China,Enterprise Innovation ...
... access to 'Best Practices for Long-term Jatropha ... Rajagopal's highly successful November 2007 position paper ... is being offered. It emphasizes the need ... it nears commercialization as a viable alternative ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... 2007 - Two carotid stenting trials examining patient ... established by the American Heart Association (AHA) for ... of these studies were presented today at the ... (TCT) scientific symposium by William A. Gray, M.D., ...
... available in German . The coal tit ... together for their whole lives. That,s only a facade. This ... is what research by biologists at the University of Bonn ... than 200 breeding couples and their young. In this way ...
... that mate (mah tā) tea drinkers had experienced a ... promotes HDL (good) cholesterol while lowering LDL (bad) cholesterol, ... Argentina where mate tea has been grown and taken ... agreement signed by administrators of La Universidad Nacional de ...
Cached Biology News:2 carotid artery stenting studies show results comparable to AHA guidelines 22 carotid artery stenting studies show results comparable to AHA guidelines 3Age increases chance of success as two-timer 2Age increases chance of success as two-timer 3More on mate tea: lower cholesterol and an international agreement 2
Request Info...
... Partially purified chicken intestinal cytoplasmic 1,25-(OH)2D3 ... receptor (VDR) from human, rat, mouse, ... This antibody does not cross-react ... MA1-710 detects both the occupied and ...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... is ideal for high-fidelity amplification of ... as cloning and mutagenesis. High ... enzyme preparation containing recombinant DNA polymerase ... Site5' exonuclease) activity. Platinum Anti-Pfx ...
Biology Products: